PreDiCT-TB Consortium

Finding the most rapid and reliable ways of identifying the most potent combinations of new drugs and hasten their ability to be used clinically.
Other Business 2
Pharma (non-IFPMA member) 1
Academia or research institute 12
Private Foundation or Development Organization 1
Technology 2
Intergovernmental Organizations and Multilaterals 2
Government 1
  • To find the most rapid and reliable ways of identifying the most potent combinations of new drugs and hasten their ability to be used clinically.

What are the health needs and challenges?

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis. It usually affects the lungs causing coughing, fever and weight loss. Although the disease has long been both preventable and curable, TB is one of the top 10 causes of death and the leading cause from a single infectious agent. Treatment requires six months or more of combinations of antibiotics to ensure complete cure and more effective drugs are urgently needed to shorten treatment.

Partnership activities and how they address needs and challenges

PreDiCT-TB was a public-private partnership funded by the EU Innovative Medicines Initiative, comprising three major pharmaceutical partners (GSK, Sanofi, and Janssen Pharmaceutical Companies of Johnson & Johnson), two biotechnology firms (ZF Screens and Microsens Medtech) and fifteen academic partners headed by the University of Liverpool. The multidisciplinary consortium brought together experts in microbiology, pharmacology, engineering, mathematical modelling, and clinical trials to create a new integrated framework for TB drug development, making optimal use of preclinical information to design the most efficient clinical trials.

PreDiCT-TB aimed to overcome disconnects in TB drug development by adopting a fully integrated multidisciplinary approach grounded in pharmacokinetic (PK) – pharmacodynamic (PD) analysis and calibrated by clinical outcomes. By effectively integrating preclinical information into the early clinical phase, the Consortium aimed to provide a new framework and tools that facilitated the transition of the best combinations of drugs to late phase development and maximise their chances of success.

Results and milestones

For Publications which resulted from this Consortium please see

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Women
  • Men
  • People with low incomes
SGDs the partnership contributes to
SDG 3: Good Health and Wellbeing
  1. 3.3: Communicable Diseases & NTDs
  2. 3.8: Achieve universal health coverage
SDG 5: Gender Equality
SDG 9: Industry Innovation and Infrastructure
SDG 10: Reduced Inequalities
SDG 17: Partnerships for the Goals 
Partner organizations
Other Business

Pharma (non-IFPMA member)


Pharma (non-IFPMA member)


Academia or research institute

École Polytechnique Fédérale de Lausanne (EPFL)

Erasmus University

Instituto De Salud Carlos III

Liverpool School of Tropical Medicine

Max Plank Institute

St George's, University of London

University College London

University of Leicester

University of Liverpool

University of St. Andrews

University of Sussex

Uppsala University

Private Foundation or Development Organization

Institute Pasteur


Microsens Medtech


Intergovernmental Organizations and Multilaterals

European Commission

European Union


Public Health England

Additional information